World Pharma News

Lu AA24530 shows positive results in major depressive disorder phase II study

2009-07-04T00:00:00+01:00

H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).

Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer

2009-07-03T00:01:00+01:00

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

2009-07-03T00:00:00+01:00

Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.

Bayer files patent infringement lawsuit against Teva

2009-07-02T00:01:00+01:00

Bayer Schering Pharma AG, Germany and Bayer HealthCare Pharmaceuticals Inc. together with Schering Corporation have filed a patent infringement lawsuit in the U.S. Federal Court in the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.

IRESSA (Gefitinib) Receives Marketing Authorisation in Europe

2009-07-02T00:00:00+01:00

AstraZeneca announced that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) across all lines of therapy.

Pfizer Discontinues Phase 3 Trial of Sutent� in Metastatic Colorectal Cancer

2009-07-01T01:05:24+01:00

Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent� (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC).

AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400

2009-07-01T00:00:00+01:00

AstraZeneca announced that its development partner, Pozen, Inc., has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for VIMOVO (PN400) (enteric coated naproxen/esomeprazole magnesium) tablets, a product under investigation for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated ulcers.

Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets

2009-06-30T00:00:00+01:00

Bayer Schering Pharma AG, Germany, has entered into an exclusive license agreement with Celera Corporation, California, USA, providing Bayer Schering Pharma with access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. These therapeutic targets were identified by Celera's proteomics discovery platform.

Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities

2009-06-29T00:00:00+01:00

Novo Nordisk has reached a settlement with the Danish Public Prosecutor for Serious Economic Crime regarding the company's sales to Iraq during 2000 to 2003 under the United Nations Oil-for-Food programme.

Lundbeck receives FDA Complete Response Letter on Serdolect� for the treatment of schizophrenia

2009-06-26T00:01:00+01:00

H. Lundbeck A/S (LUN.CO; LUN DC) has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for Serdolect� (sertindole) for the treatment of schizophrenia.